Resources
Blog: Read the latest post
How to improve biopharma business development with AI-powered due diligence
April 7, 2025
Biopharma business development and scientific teams are under a lot of pressure to identify the next big program for their indication and strategy.
Webinar: Watch on-demand
Watch this webinar with Alok Tayi, PhD, Founder and CEO of Vibe Bio, to learn on how AI is accelerating the business development process, helping executive teams move faster by making it easier to collect, manage, access, and evaluate drug assets, thus empowering them to conduct more thorough due diligence with the same resources.
Additional resources
Biopharma business development and scientific teams are under a lot of pressure to identify the next big program for their indication and strategy.
I recently sat down with a Top 20 pharmaceutical company to discuss their goals and struggles for the year ahead and how pharma portfolio analytics fits in.
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
Chinese biopharma companies are at an inflection point, with rapidly advancing in science, know-how, + talent. Chinese assets are poised to reshape drug development.
Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.
By combining human expertise with AI-powered analysis, we're helping biopharma companies make faster, more informed business development decisions.
Uncover new possibilities with VibeOne
Learn how VibeOne can help you discover your next indication or identify high potential development opportunities in your portfolio.
